Are you Dr. Eckhardt?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 54 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1601 Trinity St
Austin, TX 78712Phone+1 512-495-5512
Summary
- Dr. Sue Eckhardt, MD is an oncologist in Austin, Texas. She is currently licensed to practice medicine in Texas, Colorado, and California. She is affiliated with Ascension Seton Medical Center Austin.
Education & Training
Scripps Clinic/Scripps Green HospitalFellowship, Medical Oncology, 1988 - 1990
University of Virginia Medical CenterInternship, Internal Medicine, 1985 - 1986
University of Texas Medical Branch School of MedicineClass of 1985
Certifications & Licensure
CA State Medical License 1988 - Present
TX State Medical License 1993 - 2026
CO State Medical License 1999 - 2019- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2006-2014
- America's Top Doctors for Cancer Castle Connolly, 2006-2013
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Join now to see all
Clinical Trials
- PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas Start of enrollment: 2006 Mar 01
- Collection and Storage of Tissue and Blood Samples From Patients With Cancer Start of enrollment: 2015 May 19
Publications & Presentations
PubMed
- 46 citationsA phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer.Jennifer R. Diamond, S.G. Eckhardt, Todd M. Pitts, Adrie van Bokhoven, Dara L. Aisner
Breast Cancer Research. 2018-08-02 - 57 citationsPhase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor, in Patients with Advanced Solid TumorsJennifer R. Diamond, Bruno R. Bastos, Ryan J. Hansen, Daniel L. Gustafson, S. Gail Eckhardt
Clinical Cancer Research. 2011-02-15 - 45 citationsPhase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors...Wen Wee Ma, Wells A. Messersmith, Grace K. Dy, Colin D. Weekes, Amy Whitworth
Clinical Cancer Research. 2012-04-01
Press Mentions
Houston Cancer-Fighting Organization Launches Center to Support Early TrialsSeptember 3rd, 2024- Dan L Duncan Comprehensive Cancer Center Launches Phase 1 Clinical Trial ProgramAugust 19th, 2024
